JP2018538356A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538356A5
JP2018538356A5 JP2018536700A JP2018536700A JP2018538356A5 JP 2018538356 A5 JP2018538356 A5 JP 2018538356A5 JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018538356 A5 JP2018538356 A5 JP 2018538356A5
Authority
JP
Japan
Prior art keywords
variant
igf
mutations
bispecific protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536700A
Other languages
English (en)
Japanese (ja)
Other versions
JP7005019B2 (ja
JP2018538356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/054744 external-priority patent/WO2017059231A1/en
Publication of JP2018538356A publication Critical patent/JP2018538356A/ja
Publication of JP2018538356A5 publication Critical patent/JP2018538356A5/ja
Priority to JP2021159345A priority Critical patent/JP7365715B2/ja
Application granted granted Critical
Publication of JP7005019B2 publication Critical patent/JP7005019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536700A 2015-10-02 2016-09-30 組織修復のための二重特異性治療用タンパク質 Active JP7005019B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021159345A JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562236169P 2015-10-02 2015-10-02
US62/236,169 2015-10-02
US201562237889P 2015-10-06 2015-10-06
US62/237,889 2015-10-06
US201662322910P 2016-04-15 2016-04-15
US62/322,910 2016-04-15
PCT/US2016/054744 WO2017059231A1 (en) 2015-10-02 2016-09-30 Bi-specific therapeutic proteins for tissue repair

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021159345A Division JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Publications (3)

Publication Number Publication Date
JP2018538356A JP2018538356A (ja) 2018-12-27
JP2018538356A5 true JP2018538356A5 (enExample) 2019-12-26
JP7005019B2 JP7005019B2 (ja) 2022-02-04

Family

ID=58427983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018536700A Active JP7005019B2 (ja) 2015-10-02 2016-09-30 組織修復のための二重特異性治療用タンパク質
JP2021159345A Active JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021159345A Active JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Country Status (7)

Country Link
US (6) US10040840B2 (enExample)
EP (2) EP3865147B1 (enExample)
JP (2) JP7005019B2 (enExample)
CN (2) CN115960249A (enExample)
CA (1) CA3000742A1 (enExample)
ES (1) ES2863278T3 (enExample)
WO (1) WO2017059231A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
CA3000742A1 (en) * 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞
JP7355326B2 (ja) * 2019-08-05 2023-10-03 デンカ株式会社 経粘膜投与薬剤
PE20220401A1 (es) * 2019-09-06 2022-03-22 Novartis Ag Proteinas de fusion terapeuticas
CN112584507B (zh) 2019-09-30 2022-05-17 华为技术有限公司 一种数据处理方法、装置及存储介质
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
US20220031812A1 (en) * 2020-07-30 2022-02-03 Silver Creek Pharmaceuticals, Inc. Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders
KR20240021898A (ko) * 2021-06-14 2024-02-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 아넥신 a5 폴리펩타이드 및 치료 목적을 위한 이의 용도
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
US20240279359A1 (en) * 2021-06-30 2024-08-22 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for targeted delivery of growth factors to the glomerulus
US20250144175A1 (en) * 2022-02-15 2025-05-08 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for treatment of acute radiation syndrome
WO2025207443A1 (en) * 2024-03-25 2025-10-02 Cavalry Biosciences, Inc. Igf-1-related compositions and uses of the same

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL269416A (enExample) 1960-09-21
GB8819826D0 (en) 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
US5679771A (en) 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
JP3664727B2 (ja) * 1994-01-24 2005-06-29 ネオルクス コーポレイション 放射標識したアネキシン
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
JPH11508608A (ja) 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ,インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
BR9912053A (pt) 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2378925C (en) 1999-07-21 2010-04-06 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
JP2001251104A (ja) 2000-03-03 2001-09-14 Murata Mfg Co Ltd 非可逆回路素子及び通信機装置
ATE463252T1 (de) 2000-08-29 2010-04-15 Aurogen Inc Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
AU2008200706B2 (en) 2001-10-16 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2003241313A1 (en) 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
CN1659180B (zh) 2002-06-06 2010-06-02 温子坚 新型的重组抗凝血蛋白
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040213738A1 (en) 2003-03-31 2004-10-28 Susan Croll-Kalish CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
BRPI0406605B8 (pt) * 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
JP2008510732A (ja) 2004-08-20 2008-04-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 心臓組織の損傷を処置、予防、阻害、または緩和する方法
WO2006023879A1 (en) 2004-08-20 2006-03-02 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
AU2006203882B2 (en) 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
EP1841467A4 (en) 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
CA2591914C (en) 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
CN101163501A (zh) 2005-02-23 2008-04-16 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
US7521211B2 (en) 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CA2609728A1 (en) 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CA2618476A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン,エルエルシー タンパク質製剤
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
SE0700218L (sv) 2007-01-23 2008-02-26 Teknikbolaget K Samuelsson Ab Sprutmunstycksanordning för brandsläckningssystem
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US8889140B2 (en) 2007-05-31 2014-11-18 Transtarget, Inc. Compositions and methods for tissue repair
EP2152751A1 (en) 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
WO2009030720A2 (en) 2007-09-06 2009-03-12 Novozymes Biopharma Dk A/S Process for producing a recombinant protein
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2751068A1 (en) * 2009-01-31 2010-08-05 Igf Oncology, Llc Anti-cancer protein-platinum conjugates
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
UA103104C2 (ru) 2009-07-22 2013-09-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
JP2013507926A (ja) 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
JP5875597B2 (ja) 2010-12-08 2016-03-02 ヴィアサイト,インコーポレイテッド ヒト万能性幹細胞の成長を阻害する薬剤および方法
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CN104011070A (zh) 2011-12-15 2014-08-27 爱德迪安(北京)生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
JP2016515587A (ja) 2013-03-29 2016-05-30 メリマック ファーマシューティカルズ インコーポレーティッド 軟骨結合性融合タンパク質
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair

Similar Documents

Publication Publication Date Title
CN104507961B (zh) 抗炎性肽及包含其的组合物
JP6809789B2 (ja) 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
CA2926262C (en) CYSTEINE MODIFIED TYPE III FIBRONECTIN DOMAIN BINDING MOLECULES (FN3)
US8278413B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2021522790A5 (enExample)
AU2012277376B2 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2015522576A5 (enExample)
JP2023518596A5 (enExample)
JP2020506701A (ja) 組織特異的Wntシグナル増強分子およびその使用
JP2019522465A5 (enExample)
JP2019510739A5 (enExample)
JP2014510518A5 (enExample)
JP2017538401A5 (enExample)
JP2023528207A5 (enExample)
JP2015525217A5 (enExample)
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
JP2018523483A5 (enExample)
JP2019530441A5 (enExample)
CN115960249A (zh) 用于组织修复的双特异性治疗性蛋白质
JP2017531613A5 (enExample)
JP2017521074A5 (enExample)
JP2017141225A5 (enExample)
JP2014517690A5 (enExample)
CN111601815A (zh) 靶向细胞中c-Myc的嵌合分子
CA3157785A1 (en) Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof